Media

Here in the media centre you will find a range of resources including our latest and archived press releases of China. For global press releases, please visit Media on gsk.com

Press releases

Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

•150 healthy adult and elderly participants expected to be enrolled in Phase 1 study <br/> •COVID-19 vaccine candidate to be evaluated in combination with GSK’s pandemic adjuvant system and Dynavax’s CpG 1018 adjuvant following promising preclinical study results <br/> •Preliminary safety and immunogenicity results expected in August 2020 <br/> •Global Phase 2b/3 vaccine efficacy study is in planning stage, targeting initiation by year-end 2020

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

•Interim analysis from HPTN 083 study shows investigational, long-acting injectable cabotegravir (CAB LA) administered every two months is 69% more effective than daily pills in preventing HIV acquisition <br/> •Participants who were in the daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg (FTC/TDF) tablet arm of the study will be offered CAB LA <br/>